glp-1 receptor agonist dry eye Characterization and Role of Glucagon-Like Peptide 1 in the Lacrimal Gland: Novel Insights into Diabetic Pathogenesis GLP-1 medications and eye problem

Description

To view a copy of this licence, visit About this article Cite this article Quddos, F., Fowler, M., de Lima Bovo, A.C

Incretin-Based Glucose-Lowering Medications and the Risk of Acute Pancreatitis and Malignancies: A Meta-Analysis Based on Cardiovascular Outcomes Trials

Through continuous innovation and technological progress, peptibody drugs are poised to bring safer and more effective treatment options for patients in the future, driving advancements in the field of biomedicine.

Understanding Obesity as a Chronic Condition Its crucial to recognize that obesity is a chronic medical condition, not a temporary issue that can be solved with a quick fix

7.1 Comparing with the conventional hypoglycemic agents Compared with DDP-4i, GLP-1RAs showed better results in reducing the risk of cirrhosis and mortality (Yang et al., 2024)